---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-008414"
form_type: "8-K"
ticker: "CMPS"
cik: "0001816590"
company_name: "COMPASS Pathways plc"
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:24:47.290429+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Compass Pathways reports FY2024 net loss of $155.1M; Phase 3 data on track for Q2 2025

## Summary
- Net loss for FY2024 was $155.1M ($2.30 loss per share) vs $118.5M ($2.32 loss per share) in FY2023.
- Cash and cash equivalents $165.1M at Dec 31, 2024; additional $140.4M net raised in Q1 2025.
- Phase 3 COMP005 top-line 6-week data for TRD on track for Q2 2025; COMP006 26-week data expected H2 2026.
- R&D expenses rose to $119.0M from $87.5M, driven by phase 3 trials and strategic reorganization costs.
- Steve Levine, M.D., appointed Chief Patient Officer.

## SEC filing metadata
- accession: 0001628280-25-008414
- form_type: 8-K
- ticker: CMPS
- cik: 0001816590
- company_name: COMPASS Pathways plc
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816590/000162828025008414/0001628280-25-008414-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816590/000162828025008414/cmps-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-008414
- JSON: https://secwatch.observer/filing/0001628280-25-008414.json
- Plain text: https://secwatch.observer/filing/0001628280-25-008414.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.